Sentences with phrase «drug olaparib»

Men with prostate cancer benefit from treatment with the pioneering drug olaparib — the first cancer drug to target inherited mutations — according to the results of a major trial.

The trial compared the activity of the combination of the drug olaparib, which blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs. olaparib alone.

«Murine study finds potential boost for ovarian cancer drug Olaparib.»

Not exact matches

It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.

PARP (Poly ADP - Ribose Polymerase) inhibitors, such as olaparib, are targeted drugs that block an enzyme involved in many functions in the cell, including the repair of DNA damage.

These encouraging results show that olaparib could be the next drug to add to those already available.

Of the 16 patients with detectable DNA repair mutations, 14 responded to olaparib — accounting for the large majority of patients who benefited from the drug.

Zhang's team began by combining the PARP inhibitor olaparib with 20 different helper compounds, and eventually discovered a family of drugs called BET inhibitors that work with olaparib to attack cancer cells.

Hence, a total of 90 patients from nine centers were randomly assigned to one of two study arms for the phase II clinical trial: the first taking capsules of olaparib (400 mg twice daily) and the other taking a combination of the two drugs (200 mg olaparib in capsule - form twice daily and 30 mg tablets of cediranib once daily).

«This is the first study to test the promise of a new kind of drug, olaparib, for life - threatening prostate cancer no longer responding to best available treatment.

They found that tumor cells with the mutant genes were particularly sensitive to a drug, olaparib, recently approved for the treatment of hereditary ovarian cancer.

Tumours shrank in about 60 % of women who received the targeted drug, called olaparib (Lynparza), compared with 29 % of those who received chemotherapy.

He is currently leading the TOPARP trial, which is finding out whether a drug called olaparib (Lynparza) improves survival for men with advanced prostate cancer that has stopped responding to treatment.

Treating women with olaparib, a new type of experimental drug called a PARP inhibitor, after their initial cancer treatment, may help prevent their ovarian cancer from coming back, according to a phase - II clinical trial led by UK scientists.

The researchers also identified a way to safely combine both drugs by giving olaparib intermittently, minimising dangerous side effects.